Comparison 6. Topical salicylic acid versus no treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Participants' global self‐assessment of acne improvement	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.1 moderate to excellent improvement (long term)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.2 Withdrawal for any reason	3		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.2.1 long term	3		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3 Change in lesion counts ‐ total (percentage reduction from baseline)	3		Other data	No numeric data
6.4 Change in lesion counts ‐ inflamed (percentage reduction from baseline)	2		Other data	No numeric data
6.5 Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline)	2		Other data	No numeric data
6.6 Physicians' global evaluation of acne improvement	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.6.1 moderate to excellent improvement (long term)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.7 Minor adverse events	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.7.1 dryness	1	50	Risk Ratio (M‐H, Random, 95% CI)	2.67 [1.25, 5.68]
6.7.2 peeling	1	50	Risk Ratio (M‐H, Random, 95% CI)	1.50 [0.74, 3.03]
6.7.3 erythema	1	50	Risk Ratio (M‐H, Random, 95% CI)	4.00 [0.94, 17.00]
6.7.4 burning	1	50	Risk Ratio (M‐H, Random, 95% CI)	1.67 [0.71, 3.89]
6.7.5 itching	1	50	Risk Ratio (M‐H, Random, 95% CI)	1.67 [0.45, 6.24]
6.7.6 total events (long term)	2	78	Risk Ratio (M‐H, Random, 95% CI)	3.43 [0.14, 82.00]
6.8 Quality of life (QoL) ‐ AQOL (score, post‐intervention)	1		Other data	No numeric data